Concurrent chemoradiotherapy in limited-stage small-cell lung cancer. Results of a pilot study

Abstract

Between January 1994 and February 1998, 32, limited-stage small-cell lung cancer patients were treated with concurrent chemoradiotherapy. Follow-up time ranged from 4 to 34 months, (median 14 months). Complete regression was obtained in 22 of the 30 patients, who received at least four courses of EP chemotherapy and a tumour dose of 50 Gy or more. In all, 2-year actuarial disease-free survival was 21 %. Brain metastases occurred in 8 (36.4 %) patients with CR, in 5/7 (71.4 %) patients without prophylactic cranial irradiation (PCI) and in 3/15 (20 %) patients after PCI. The survival rate was lower in patients with PCI, in Whom chest irradiation was started later than one month from the beginning of course 1 of EP chemotherapy. We have suggested a modification of the treatment protocol.